Identification and Validation of Major Cardiovascular Events in the United Kingdom Data Sources Included in a Multi-database Post-authorization Safety Study of Prucalopride by Ruigómez, Ana et al.
                                                                    
University of Dundee
Identification and Validation of Major Cardiovascular Events in the United Kingdom
Data Sources Included in a Multi-database Post-authorization Safety Study of
Prucalopride
Ruigómez, Ana; Plana, Estel; Gilsenan, Alicia; Fortuny, Joan; Cainzos-Achirica, Miguel;








Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Ruigómez, A., Plana, E., Gilsenan, A., Fortuny, J., Cainzos-Achirica, M., Flynn, R. W. V., MacDonald, T. M.,
Garcia-Rodriguez, L., Ziemiecki, R., & Andrews, E. B. (2021). Identification and Validation of Major
Cardiovascular Events in the United Kingdom Data Sources Included in a Multi-database Post-authorization
Safety Study of Prucalopride. Drug Safety. https://doi.org/10.1007/s40264-021-01044-4
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.





Identification and Validation of Major Cardiovascular Events 
in the United Kingdom Data Sources Included in a Multi‑database 
Post‑authorization Safety Study of Prucalopride
Ana Ruigómez1 · Estel Plana2 · Alicia Gilsenan3 · Joan Fortuny2 · Miguel Cainzos‑Achirica4,5 · Robert W. V. Flynn6 · 
Thomas M. MacDonald6 · Luis Garcia‑Rodriguez1 · Ryan Ziemiecki3 · Elizabeth B. Andrews3
Accepted: 11 January 2021 
© The Author(s) 2021
Abstract
Introduction A multinational post-authorization safety study assessed cardiovascular safety in initiators of prucalopride for 
chronic constipation compared with a matched cohort of polyethylene glycol 3350 initiators. The primary safety outcome 
was major adverse cardiovascular events (MACE), a composite of hospitalization for acute myocardial infarction, stroke, 
or in-hospital cardiovascular death. We report the validation process for MACE endpoints in United Kingdom (UK) data 
sources: Clinical Practice Research Datalink (CPRD GOLD), The Health Improvement Network (THIN), and the Informa-
tion Services Division (ISD) Scotland.
Methods Modified electronic algorithms from prior research identified potential MACE cases. Validation followed a com-
mon protocol, adapted for each database, with all information anonymized: (1) direct confirmation via linkage to hospital 
records (CPRD GOLD); (2) requests for additional clinical information through questionnaires (CPRD GOLD), free-text 
(THIN), or abstraction of hospital records (ISD); (3) manual review of electronic records of potential events retrieved by the 
algorithm (CPRD GOLD/THIN); and (4) event adjudication by three clinicians, blinded to exposure, for all remaining events.
Results Electronic algorithms identified 260 potential MACE cases: 38 confirmed via linkage to hospital records (CPRD 
GOLD), 56 ruled out as non-cardiovascular death cases (THIN), and three unavailable for review (ISD), leaving 163 poten-
tial cases. After manual review with additional information (steps 2 and 3), 45 were considered noncases (CPRD GOLD/
THIN). Upon final adjudication (step 4), remaining potential events were adjudicated as definite (n = 62), probable (n = 10), 
possible (n = 13), or noncases (n = 33).
Conclusions Given the limitations of relying solely on computer algorithms to identify cardiovascular outcomes, validation 
with clinical review is essential to guide interpretation.
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1 Introduction
Prucalopride (Resolor) is a 5-hydroxytryptamine receptor 
type 4 (5-HT4) agonist approved for the treatment of chronic 
constipation [1]. On regulatory request, a post-authorization 
safety study (PASS) was conducted in 2016–2017 to assess 
the cardiovascular safety of prucalopride by comparing the 
occurrence of cardiovascular events among initiators of this 
drug and among a matched comparator cohort of polyethyl-
ene glycol 3350 (PEG) initiators [2, 3].
The study was conducted in five European data sources: 
the Clinical Practice Research Datalink (CPRD GOLD), the 
Health Improvement Network (THIN), and the Information 
Services Division (ISD) Scotland in the United Kingdom 
(UK); the German Pharmacoepidemiological Research 
Database (GePaRD); and the Swedish National Registries 
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Key Points 
In this population-based, multinational post-authori-
zation safety study to evaluate cardiovascular safety in 
initiators of prucalopride versus a matched cohort of 
polyethylene glycol 3350 (PEG) initiators, major adverse 
cardiovascular events (MACE) endpoints were identified 
using electronic algorithms.
Validation of MACE endpoints followed a common pro-
tocol, adapted for each of three United Kingdom (UK) 
data sources: Clinical Practice Research Datalink (CPRD 
GOLD), The Health Improvement Network (THIN), and 
Information Services Division (ISD) Scotland.
Validation occurred through direct confirmation via link-
age to hospital records, requests for additional clinical 
information, manual review of potential events retrieved 
by electronic algorithms, and adjudication of potential 
events by clinicians who were blinded to exposure.
Of 260 potential MACE events identified by the elec-
tronic algorithms (108 from CPRD GOLD, 79 from 
THIN, and 73 from ISD), 100 were considered actual 
events after identification of confirmed events, review, 
and the adjudication process. Given the limitations of 
electronic algorithms to identify cardiovascular out-
comes, validation with clinical review is essential.
2  Methods
2.1  PASS Setting, Data Sources, and Study Design
As noted previously, details on the research methods and 
study results of the prucalopride PASS have been reported in 
detail elsewhere [2, 3]. Briefly, this was a population-based, 
observational, retrospective cohort study of adult patients 
with chronic constipation initiating either prucalopride or 
PEG (matched on a 1:5 ratio), from the UK, Sweden, and 
Germany. Cohorts of new users were followed from date of 
first prescription of study drug until first MACE (i.e., hospi-
talization due to AMI or stroke or in-hospital cardiovascular 
death), death due to other reasons, end of data collection, or 
end of study period. The study compared the risk of MACE 
in prucalopride users versus PEG users, pooling the infor-
mation from five large health care databases: CPRD GOLD, 
THIN, ISD Scotland, GePaRD, and SNR.
Event validation for the primary study endpoint was per-
formed only in the UK data sources. Validation via medical 
record review was not performed in the SNR or GePaRD 
for this study. However, clinical data from the SNR and 
GePaRD have been previously validated and determined 
to be of good quality [9–12]. The characteristics of these 
three databases (CPRD GOLD, THIN, and ISD Scotland) 
have been reported previously [3]. Briefly, CPRD GOLD 
is a database derived from electronic medical records from 
general practices and includes linkage to Hospital Episode 
Statistics (HES) for inpatient data and to Office of National 
Statistics (ONS) data for cause-of-death data for some par-
ticipating practices. THIN is a primary care database with no 
link to ONS or HES, but with access to anonymized free-text 
comments entered by treating general practitioners (GPs) at 
the time of this study. ISD Scotland is a data source derived 
from the linkage of routinely collated dispensing, hospitali-
zation, and death certification data.
2.2  PASS Endpoint Definitions
The primary endpoint of the prucalopride PASS was first 
occurrence of a MACE within the study period (2010–2016), 
defined as the composite of hospitalization for nonfatal AMI 
[13, 14], hospitalization for nonfatal stroke (either ischemic 
or hemorrhagic) [15], and in-hospital cardiovascular death. 
For the latter, a very broad definition was used, aimed at 
ensuring that any potential in-hospital cardiovascular death 
would be detected as a potential study endpoint. This defini-
tion included deaths from AMI, stroke, heart failure, cardio-
vascular hemorrhage, sudden cardiac death, cardiovascular 
procedures (coronary revascularizations), and other cardio-
vascular deaths [14]. Individual components of MACE were 
also evaluated separately as secondary study endpoints.
(SNR) [4]. The primary endpoint of the PASS was occur-
rence of a MACE, defined as first occurrence of any of the 
following endpoints: hospitalization for nonfatal acute myo-
cardial infarction (AMI), hospitalization for nonfatal stroke, 
or in-hospital cardiovascular death.
Potential clinical endpoints during the study period were 
identified using electronic algorithms in the five databases. 
Although the validity of MACE endpoint definitions has 
been established in databases from both Europe and the 
United States [5–8], validation of study endpoints by clini-
cal experts was planned a priori as part of the prucalopride 
PASS in the three databases for which this was expected to 
be feasible during the study period: CPRD GOLD, THIN, 
and ISD Scotland.
Here, we describe the methodology and results of the 
event identification and validation for MACE in the three 
UK data sources conducted as part of the prucalopride 
multidatabase PASS. The PASS aimed to provide standard-
ized estimates of incidence rates and incidence rate ratios 
of MACE among initiators of prucalopride compared with 
PEG initiators, and methods and results for the PASS are 
reported elsewhere [2, 3].
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2.3  Electronic Ascertainment of Potential Events
Potential study events were identified in all databases 
using modified versions of previously reported automated 
algorithms [16–20], which included diagnosis and proce-
dure codes (International Classification of Diseases [ICD] 
codes and/or codes from local dictionaries). Supplemen-
tary Table S1 summarizes the codes used to define each 
study endpoint (see the electronic supplementary material). 
Compared with the published definitions, the algorithms 
underwent minor modifications after clinical review by 
study investigators to harmonize them across sources and 
to account for limitations in data availability.
The diagnosis codes were combined with additional qual-
ifiers (e.g., hospital admission components) in operational 
definitions that also provided a preliminary, automated clas-
sification of the study endpoints as “confirmed,” “definite,” 
“probable,” or “possible” cases, as well as “unknown cause 
of death” specifically for fatal events (Table 1).
In each data source, hospitalizations for nonfatal AMI and 
nonfatal stroke were identified by hospital discharge diagno-
sis codes in patients discharged alive from the hospital. In-
hospital cardiovascular deaths were identified through pri-
mary cardiovascular discharge diagnoses or the underlying 
cause-of-death codes when these data were available (CPRD 
GOLD and THIN). Patients admitted to the hospital for a 
noncardiovascular cause, regardless of whether it resulted 
in a cardiovascular cause of death, were initially consid-
ered potential cases, and further information was collected, 
if available. However, if there was no clear cardiovascular 
cause of hospitalization, the event was not considered a rel-
evant outcome for this study. In THIN, because linkage to 
HES/ONS was not possible, any (i.e., all-cause) in-hospital 
deaths were considered for review at this stage, and a pre-
liminary additional manual plausibility evaluation of these 
death events was conducted before considering them poten-
tial cardiovascular death study endpoints.
2.4  Case Validation
After all potential study endpoints (including all occurrences 
during the study follow-up period, not just first occurrence) 
from the three UK data sources were identified electroni-
cally (and provided a preliminary classification), duplicate 
cases between THIN and CPRD GOLD were removed from 
the THIN data source (as described in Fortuny et al. [3]). 
The approach taken to ensure removal of duplicate patients 
involved (1) eliminating all the Scottish practices from the 
CPRD and THIN since they were also included in the ISD 
Scotland database and (2) excluding potentially duplicated 
practices in THIN and CPRD. Using a modified six-step 
algorithm based on patient-level demographic and phar-
macy data [21], we identified patients thought to be the same 
individual in the CPRD and THIN without compromising 
patient or practice confidentiality. In case of duplication, 
CPRD practices were retained and their equivalents in THIN 
were removed.
Validation was conducted for all potential study end-
points. Validation occurred per the following four general 
steps: (1) identification of electronically confirmed cases and 
direct confirmation via linkage to hospital records (CPRD 
GOLD only); (2) request for additional clinical information 
through questionnaires (CPRD GOLD), free-text (THIN), or 
original hospital case records (ISD); (3) manual review by 
study investigators of the preliminary patient profiles (e.g., 
database listings of outpatient visits, procedures, and medi-
cations) of events retrieved by the algorithm (CPRD GOLD/
THIN) to rule out noncases; and (4) event adjudication by 
the prucalopride PASS adjudication committee (three cli-
nicians, all blinded to exposure). This common validation 
protocol had to be adapted to the resources and type of data 
available in each data source.
2.4.1  Case Validation in the CPRD GOLD
In CPRD GOLD (Fig. 1), potential cases were considered 
confirmed (with no additional validation needed) through 
hospital discharge diagnoses from HES data if any of the 
following occurred: (1) for nonfatal events, the primary hos-
pital discharge diagnosis codes were consistent with the list 
of codes from the study protocol (Supplementary Table S1, 
see the electronic supplementary material); and (2) for in-
hospital deaths, the death occurred in the hospital (identified 
in HES) and the underlying cause-of-death codes from ONS 
were consistent with the list of codes from the study protocol 
(see Supplementary Table S1).
For nonconfirmed potential cases, questionnaires were 
sent to the treating GPs. To complete the questionnaires, GPs 
were asked to review the medical records in their posses-
sion, including hospital discharge reports, autopsy reports, 
death certificates (if available to the GP), and free-text, and 
to complete a specific questionnaire designed for each end-
point. Review of free-text comments was also originally 
planned, but eventually these became unavailable during 
the study conduct due to data privacy reasons implemented 
throughout CPRD GOLD.
Using the information included in automated patient 
profiles and in available GP questionnaires, a preliminary 
adjudication/classification was conducted by trained epi-
demiologists so that obvious noncases could be excluded 
from the subsequent adjudication review. The investigators 
were blinded to exposure status, and the classifications and 
criteria used were the same as the ones used by the elec-
tronic algorithms for their preliminary classification, plus 
“noncase” (i.e., potential cases not meeting any of the prior 
definitions). Potential cases classified as noncases by one 
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epidemiologist were reviewed by a second one and, when 
in agreement, were not considered as a case in the study. 
The remaining potential cases were reviewed by the study 
adjudication committee.
2.4.2  Case Validation in THIN
In THIN (Fig. 2), linkage to HES or ONS was not feasible 
for this study because of the limited number of linked prac-
tices and the long lag of data updates. Therefore, there were 
no electronically confirmed cases in this data source. As 
Table 1  Operational definitions used in the electronic algorithms for case ascertainment and used as guidelines by clinical reviewers for event 
adjudication purposes
The electronic algorithms provided a preliminary classification of all potential cases using diagnosis and procedural codes (A and B). Clinical 
reviewers conducting case adjudication used this information (A and B) together with additional sources of information (B), such as reports of 
electrocardiographic findings or of circulating troponin levels described in general practitioner questionnaires or free-text comments, among 
other sources. Possible cases of hospitalization for nonfatal AMI, hospitalization for nonfatal stroke, or in-hospital cardiovascular death not 
meeting any of the clinical definitions presented were classified as “noncases”
AMI acute myocardial infarction, ECG electrocardiogram, ESM electronic supplementary material
Hospitalization for nonfatal 
AMI
Definite Probable Possible definition 1 Possible definition 2
(A) Main codes (see Supplementary Table S1 in the ESM)
 Code for AMI Yes Yes Yes No
 Hospitalization within 
30 days of AMI
Yes Yes Yes Yes
 Death within 30 days of 
hospitalization
No No No No
(B) Additional clinical information (diagnosis and procedural codes + other sources of information)
 Chest pain ≥ 2 items recorded 30 days 
before or after the index 
AMI code
1 item recorded 30 days 
before or after the index 
AMI code
None recorded Yes, coronary chest pain
 Abnormal cardiac enzymes ≥ 1 item recorded 30 days 
before or after the index 
coronary chest pain code




Hospitalization for nonfatal stroke Definite Probable Possible
(A) Main codes (see Supplementary Table S1 in the ESM)
 Code for stroke Yes Yes Yes
 Hospitalization within 30 days of stroke Yes Yes Yes
 Death within 30 days of hospitalization No No No
(B) Additional clinical information (diagnosis and procedural codes + other sources of information)
 Referral to neurologist ≥ 2 items recorded 30 days before or 
after the index stroke code
1 item recorded 30 days before or 
after the index stroke code
None recorded
 Acute treatment for stroke
 Residual damage from stroke
 Brain imaging test, abnormal
 Neurological physiotherapy
In-hospital cardiovascular death Definite Possible Unknown
(A) Main codes (see Supplementary Table S1 in the ESM)
 Code for death with date Yes Yes Yes
 Evidence of hospitalization within 30 days of death code Yes Yes Yes
(B) Additional clinical information (diagnosis and procedural codes + other sources of information)
 Cardiovascular cause of death specifically reported Yes No No
 Evidence of AMI, stroke, sudden cardiac death, heart failure, cardiovascular hemorrhage, revasculariza-
tion procedure, or other cardiovascular event within 30 days of death code
Irrelevant Yes No
 Evidence of a non-cardiovascular condition potentially leading to death within 30 days of death code Irrelevant No No
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discussed previously, a preliminary plausibility evaluation 
(manual review of individual patient profiles) of all death 
events identified was conducted in THIN; death events for 
which there were conclusive records of an alternative, non-
cardiovascular etiology were removed from further valida-
tion steps and considered “noncases.”
GP questionnaires were not used in THIN. Instead, for 
all potential cases, any free-text comments (i.e., notes made 
by physicians regarding the patient encounter, for up to 6 
months before and after the qualifying diagnosis code or 
information on the cause of death) were requested and 
manually reviewed. As in CPRD GOLD, blinded patient 
profile review by trained epidemiologists was conducted, 
allowing for the exclusion of additional obvious noncases. 
The remaining potential cases of MACE were sent to 
adjudication.
2.4.3  Case Validation in ISD Scotland
In ISD Scotland (Fig. 3), all events were automatically con-
sidered potential, and no cases were initially considered con-
firmed. Medical record abstraction was conducted for all 
potential cases using chart abstraction forms completed by 
a team comprising a research nurse and a study doctor. All 
potential cases underwent review by the study adjudication 
committee, except for three for which clinical data could 
not be obtained.
2.5  Event Adjudication and Final Case 
Classifications
An adjudication committee of three clinical experts from the 
research partner institutions involved in validation blinded to 
the study exposure reviewed all nonconfirmed, nonexcluded 
potential cases from the three data sources and determined 
their final status using all clinical information available. 
Fig. 1  Validation process in CPRD GOLD. AMI acute myocardial 
infarction, CPRD Clinical Practice Research Datalink, GP  general 
practitioner, HES  Hospital Episode Statistics, ICD-10  International 
Statistical Classification of Diseases and Related Health Problems, 
10th Revision, ONS Office of National Statistics, QC quality control. 
aApproximately 50% of patients are linkable to HES and ONS. bDefi-
nite cases were reassigned as “confirmed” and unknown cases were 
reassigned as “noncases”; the unknown case classification applied 
only to cardiovascular deaths
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Fig. 2  Validation process in THIN. AMI  acute myocardial infarc-
tion, CV cardiovascular, GP  general practitioner, THIN The Health 
Improvement Network. aDefinite cases were reassigned as “con-
firmed” and unknown cases were reassigned as “noncases”; unknown 
case classification applied only to cardiovascular deaths.
Fig. 3  Validation process in 
ISD Scotland. If medical record 
abstraction (second green box) 
was not possible for a given 
patient, case status was assigned 
based on classification by the 
electronic algorithm. AMI acute 
myocardial infarction, ICD-
10 International Statistical 
Classification of Diseases and 
Related Health Problems, 10th 
Revision; ISD Information Ser-
vices Division, NRS National 
Records of Scotland
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Scorecards were used to document final classifications, as 
well as their rationale. Clinical reviewers attended a training 
session, in which they were provided detailed guidance on 
clinical definitions of study endpoints, on the use of score-
cards, and on the levels of certainty to be used for classifying 
study endpoints [i.e., definite, probable, and possible case; 
noncase; and unknown cause of death (Table 1)].
Two reviewers independently evaluated each potential 
case and each provided a classification. In the event of disa-
greement, a third reviewer also evaluated the event, followed 
by discussion by the full adjudication committee until a final 
classification was reached by consensus. Only those poten-
tial cases with a final classification of “confirmed” or “defi-
nite” after validation were included in the PASS main analy-
sis as MACE cases, whereas the remaining were considered 
noncases. In a sensitivity analysis, potential cases classified 
by adjudicators as “probable” (and for death events, as “pos-
sible”) were also considered to be cases.
2.6  Statistical Analyses
We described the flow of the potential cases of the primary 
study endpoint, from initial electronic identification to final 
classification after adjudication review, overall and by data 
source. In CPRD GOLD, we also described the response 
rates among the GP questionnaires sent to valid practices 
(active practices accepting questionnaires).
2.7  Research Ethics
All relevant authorities reviewed and approved the study on 
ethical grounds in the UK: the Independent Scientific Advi-
sory Committee for CPRD GOLD; the Scientific Review 
Committee for THIN; and the East of Scotland Research 
Ethics Services and the Public Benefit and Privacy Panel for 
Health and Social Care for ISD, who allowed such access for 
regulatory purposes for the first time. Any clinical informa-
tion used for validation purposes was de-identified.
3  Results
3.1  Prucalopride PASS Population from the UK
The prucalopride PASS initially included 16,426 unique 
participants from the UK before matching and trimming: 
5710 individuals from the CPRD GOLD, 3222 from THIN, 
and 7494 from ISD Scotland. The characteristics of each 
of these cohorts, overall and by treatment group, have been 
described elsewhere [2, 3].
3.2  Potential MACE Cases Identified by Electronic 
Algorithms
Figures 1, 2, 3, and 4 present the flow of the potential study 
endpoints, from initial identification to final classification, 
by database as well as overall. The electronic algorithms 
identified 260 potential events of the primary study endpoint 
in the three UK data sources: 108 identified in the CPRD 
GOLD, 79 in THIN, and 73 in ISD Scotland. These iden-
tified events could occur both within and beyond the risk 
window specified in the primary analyses.
Of the 260 potential MACE events identified by the elec-
tronic algorithms, 38 cases were considered confirmed via 
linkage to hospital records (CPRD GOLD only), 56 were 
ruled out as clear non–cardiovascular death cases (THIN) 
after review of patient records of all identified deaths, and 
three were not available for further review (ISD); the remain-
ing 163 events were considered potential cases at this point. 
After manual review with additional information, 45 were 
considered noncases (CPRD GOLD and THIN). In the final 
adjudication of the 118 remaining potential MACE cases, 62 
were adjudicated as definite, 10 as probable, 13 as possible, 
and 33 as noncases (Fig. 4). The GP questionnaire response 
rate in CPRD GOLD was 80%, free-text was available for 
all potential events from THIN, and all but three requested 
hospital case records from ISD were retrieved. This was the 
first observational study in Scotland in which access to hos-
pital case records was granted.
3.3  Validation Flow in the CPRD GOLD
Of the 108 potential cases identified, 38 were automatically 
confirmed (see criteria for automatic confirmation above) 
and did not undergo further evaluation (Fig. 1, Table 3). A 
total of 50 questionnaires were sent to valid practices, with 
a response rate of 80%. Table 2 shows the response rate for 
GP questionnaires by type of study outcome. From patient 
profile review and questionnaire information, 43 were clas-
sified as noncases, and the remaining 27 potential cases were 
reviewed by the adjudication committee. Of these, ten were 
classified as definite MACE events.
3.4  Validation Flow in THIN
Of the 79 electronic identified cases (Fig. 2, Table 3), an 
initial plausibility evaluation was performed among all 
deaths before considering them as potential MACE cases. 
This resulted in ruling out 56 deaths as in-hospital cardio-
vascular deaths (which did not undergo further validation). 
Free-text comments were requested for validation purposes 
for the remaining 23 potential cases. Patient profile review 
with free-text yielded the identification of two additional 
noncases (originally considered as one potential AMI and 
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one potential stroke), and the remaining 21 potential cases 
were sent to adjudication. Of these, 12 potential MACE 
cases were adjudicated as definite.
3.5  Validation Flow in ISD Scotland
Of the 73 potential cases identified in Scotland (Fig. 3, 
Table 3), medical chart abstraction could be performed for 
all except three potential cases (which did not undergo fur-
ther validation). Thus, 70 potential cases from ISD Scotland 
were reviewed by the adjudication committee, 40 of which 
were classified as definite MACE cases.
4  Discussion
In the UK component of the prucalopride multidatabase 
PASS, which included 16,426 unique participants prior to 
matching and trimming and after de-duplication from three 
data sources, local adaptations were needed to successfully 
implement a common event ascertainment and validation 
protocol. This included patient profile review and use of GP 
questionnaires in the CPRD GOLD; preliminary plausibil-
ity evaluation, patient profile review, and review of free-
text comments in THIN; and medical record abstraction in 
ISD Scotland. Of the 260 potential MACE events identified 
Fig. 4  Validation flowchart, all UK data sources. CPRD Clinical Practice Research Datalink, CVD cardiovascular disease, ISD Information Ser-
vices Division, THIN The Health Improvement Network, UK United Kingdom
Table 2  Description of 
the general practitioner 
questionnaire process in CPRD 
GOLD
AMI acute myocardial infarction, CPRD Clinical Practice Research Datalink, CVD cardiovascular disease






Number requested 14 18 41 73
Number sent to valid practices 6 9 35 50
Number completed 6 6 28 40
Percentage completed 100% 67% 80% 80%
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by the electronic algorithms (108 from CPRD GOLD, 79 
from THIN, and 73 from ISD), 100 were considered actual 
events after identification of confirmed events, review, and 
the adjudication process, with the CPRD GOLD being the 
largest contributor.
It is important to note that the definition used to identify 
potential causes of in-hospital cardiovascular death was, per 
regulatory request, very broad. This likely inflated the num-
ber of initial potential cases identified by the algorithms. 
Researchers conducting this type of study need to leverage 
the sensitivity of their endpoint definitions (very sensitive 
definitions yielding very few “false negatives,” but many 
“false positives”) with the resources available for case vali-
dation purposes—which may be insufficient if the potential 
number of events identified is large. In the prucalopride 
PASS, because the study population was young and death 
rates were low during the study period, using a very sensi-
tive definition generated a reasonable number of potential 
events to review. In addition, the preadjudication patient 
profile review resulted in the identification of many obvi-
ous noncases, which reduced markedly the burden on the 
adjudication committee. Furthermore, to ensure the capture 
of all MACE, all potential events identified were subject to 
validation, not only those captured during the primary event 
risk window.
Additional factors may have contributed to the difference 
in identification and case confirmation proportions, particu-
larly for in-hospital cardiovascular death events. In each data 
source, some sources of clinical information were lacking: 
for the CPRD GOLD, free-text comments were not avail-
able for validation purposes, and the response rate of the GP 
questionnaires was slightly lower than anticipated. Thus, for 
some potential CPRD GOLD cases, the patient profile was 
the only source of information for adjudicators to review. 
Linkage to the HES and ONS was possible in CPRD GOLD 
for approximately 50% of the patients. In THIN, no GP ques-
tionnaires were obtained and no linkage to the HES or ONS 
was possible. However, free-text comments were available 
for manual review for all potential cases. These features may 
have limited the ability of clinical reviewers to adjudicate 
the study events, particularly regarding assignment of cause 
of death events, for which the information included in the 
patient profiles/medical records was often very limited. This 
resulted in many events classified as “unknown” cause of 
death, which were considered noncases for analysis pur-
poses. In CPRD GOLD, in-hospital cardiovascular deaths 
Table 3  Validation of study 
outcomes by data source
AMI acute myocardial infarction, CPRD Clinical Practice Research Datalink, ISD Information Services 
Division, MACE major adverse cardiovascular events, PEG polyethylene glycol 3350, QC quality control, 
THIN The Health Improvement Network, UK United Kingdom
All UK data 
sources
CPRD GOLD THIN ISD Scotland
Total PEG/prucalopride new users 16,426 5710 3222 7494
Primary endpoint: MACE
 Electronic algorithm identification 260 108 79 73
 Excluded after initial plausibility evaluation 
(THIN)/not available (ISD Scotland)
59 – 56 3
 Potential cases for validation 201 108 23 70
 Confirmed/definite cases 100 48 12 40
Secondary endpoints: individual components of MACE
 Hospitalization for AMI
  Electronic algorithm identification 68 28 11 29
  Potential cases for validation 68 28 11 29
  Confirmed/definite cases 42 17 8 17
 Hospitalization for stroke
  Electronic algorithm identification 65 30 7 28
  Case records not available (ISD Scotland) 1 – – 1
  Potential cases for validation 64 30 7 27
  Confirmed/definite cases 33 17 3 13
 In-hospital cardiovascular death
  Electronic algorithm identification 127 50 61 16
  Excluded after initial QC check (THIN)/not 
available (ISD Scotland)
58 – 56 2
  Potential cases for validation 69 50 5 14
  Confirmed/definite cases 25 14 1 10
 A. Ruigómez et al.
comprised the majority of potential events identified by the 
algorithms compared with the other data sources.
As mentioned previously, prior published MACE clini-
cal definitions were used to create electronic algorithms to 
ascertain cases in health care databases [13–20]. A sensitiv-
ity analysis was performed that relaxed the required align-
ment with the algorithmic definitions used in the study. In 
this sensitivity analysis, where potential cases classified by 
adjudicators as “probable” (and for death events, as “pos-
sible”) were also considered to be cases, the results were 
consistent with those from the main analysis. Key lessons 
learned from this event validation exercise include the fol-
lowing: (1) the need to perform validation of outcomes in 
order to substantiate the validity of the study outcomes 
used in the analyses using these data sources; (2) the need 
to locally adapt study protocols to the disparate types of 
clinical data available in each data source; (3) the impor-
tance of using data sources with detailed clinical information 
for validation purposes, particularly for studies including 
cardiovascular death events; (4) the value of conducting 
preliminary review of potential cases in order to rule out 
obvious noncases, as a means for reducing the burden on the 
adjudication committee; and (5) the importance of involving 
clinical expert reviewers in the study validation.
5  Conclusions
A common validation protocol, with local adaptations of 
search algorithms and validations steps based on the types 
of clinical information available in each data source, allowed 
for the validation of MACE endpoints in the prucalopride 
multidatabase PASS in three UK data sources. Given the 
limitations of relying solely on computer algorithms to iden-
tify cardiovascular outcomes, validation with clinical review 
is essential to guide interpretation.
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